4,401,500 Shares in SAB Biotherapeutics, Inc. $SABS Acquired by Commodore Capital LP

Commodore Capital LP purchased a new stake in shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 4,401,500 shares of the company’s stock, valued at approximately $8,847,000. Commodore Capital LP owned approximately 0.42% of SAB Biotherapeutics as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. HB Wealth Management LLC acquired a new position in shares of SAB Biotherapeutics during the 3rd quarter valued at $618,000. Dimensional Fund Advisors LP purchased a new position in SAB Biotherapeutics in the third quarter valued at about $32,000. ADAR1 Capital Management LLC acquired a new position in shares of SAB Biotherapeutics during the third quarter worth about $30,000. Finally, Virtu Financial LLC purchased a new stake in shares of SAB Biotherapeutics in the third quarter worth about $40,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on SABS. Zacks Research lowered SAB Biotherapeutics from a “hold” rating to a “strong sell” rating in a research report on Thursday. Guggenheim began coverage on shares of SAB Biotherapeutics in a research note on Friday, December 19th. They set a “buy” rating and a $15.00 price objective on the stock. Wall Street Zen cut shares of SAB Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Chardan Capital raised their price target on shares of SAB Biotherapeutics from $12.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday. Finally, HC Wainwright dropped their price target on shares of SAB Biotherapeutics from $9.00 to $7.00 and set a “buy” rating on the stock in a research note on Tuesday, March 10th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $10.00.

SAB Biotherapeutics Stock Performance

SAB Biotherapeutics stock opened at $4.15 on Friday. SAB Biotherapeutics, Inc. has a 52 week low of $1.00 and a 52 week high of $6.60. The company has a current ratio of 9.46, a quick ratio of 10.50 and a debt-to-equity ratio of 0.02. The stock has a market cap of $211.44 million, a P/E ratio of -1.79 and a beta of 0.59. The stock has a 50 day moving average of $4.02 and a 200-day moving average of $3.37.

SAB Biotherapeutics (NASDAQ:SABS) last posted its quarterly earnings results on Monday, March 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.30). On average, analysts expect that SAB Biotherapeutics, Inc. will post -3.69 EPS for the current fiscal year.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.